{"nctId":"NCT01135992","briefTitle":"Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGINâ„¢)","startDateStruct":{"date":"2010-06"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":143,"armGroups":[{"label":"IGlar/IDeg","type":"EXPERIMENTAL","interventionNames":["Drug: insulin glargine"]},{"label":"IDeg 3TW","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec"]}],"interventions":[{"name":"insulin degludec","otherNames":[]},{"name":"insulin glargine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months\n* HbA1c maximum 10 % by central laboratory analysis\n* Current treatment with basal-oral therapy (BOT) (no prandial insulin ever) consisting of: at least three months with insulin glargine once daily (average prescribed dose must have been unchanged (within plus/minus 10%) for four weeks prior to Visit 1 as confirmed by patient records or verbal confirmation by the subject) in combination with stable (unchanged doses for at least 3 months prior to Visit 1) OAD (metformin, insulin secretagogues, pioglitazone, sitagliptin or alpha-glucosidase-inhibitor) treatment in any approved (according to label) dose or combination\n\nExclusion Criteria:\n\n* Use within the last three months prior to Visit 1 of: Exenatide, Liraglutide or Thiazoledinediones (TZDs) other than Pioglitazone\n* Cardiovascular disease (CVD) defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty within the last six months prior to Visit 1\n* Recurrent severe hypoglycaemia (more than one severe hypoglycaemic episode during the last 12 months), or hypoglycaemic unawareness as judged by the Investigator, or hospitalisation for diabetic ketoacidosis during the previous six months\n* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements\n* Previous participation in this trial. Participation is defined as started on trial medication. Rescreening of screening failures is allowed only once within the limits of the recruitment period\n* Known or suspected hypersensitivity to trial products or related products","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HbA1c (Glycosylated Haemoglobin)","description":"HbA1C at week 4 and 16","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Fasting Plasma Glucose (FPG)","description":"FPG at week 4 and 16","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"2.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Change from baseline in body weight after week 4 and after week 16","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Rate of Treatment Emergent Adverse Events (AEs)","description":"Corresponds to rate of AEs per 100 patient years of exposure. Mild AEs: no or transient symptoms, no interference with subject's daily activities. Moderate AEs: marked symptoms, moderate interference with subject's daily activities. Severe AEs: considerable interference with subject's daily activities, unacceptable. Serious adverse event (SAE): AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"370","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"250","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"424","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"280","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"409","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"273","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"453","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"424","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Nocturnal Confirmed Hypoglycaemic Episodes","description":"Rate of nocturnal confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occuring between 00:01 and 05:59 a.m.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":142},"commonTop":[]}}}